GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Net Income Including Noncontrolling Interests

NurExone Biologic (FRA:J90) Net Income Including Noncontrolling Interests : €-5.39 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

NurExone Biologic's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €-1.55 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €-5.39 Mil.

NurExone Biologic Net Income Including Noncontrolling Interests Historical Data

The historical data trend for NurExone Biologic's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Net Income Including Noncontrolling Interests Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
-1.46 -7.71 -3.34 -4.82

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -1.23 -1.13 -1.48 -1.55

NurExone Biologic Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
TSXV:SHRX TSX:HBP TSX:ONC TSX:MBX XCNQ:DTC TSXV:MIR NEOE:ONCO TSX:SVA TSXV:TTI TSXV:COV VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NRXBF:USA NRX:Canada
Address
1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Website
https://www.nurexone.com
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines